Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 5
Submit an article Journal homepage
134
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies

Thomas W. LeBlanca Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;b Duke Cancer Institute, Durham, NC, USA;c Cancer Patient Experience Research Program, Duke Cancer Institute, Durham, NC, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0546-7895View further author information
ORCID Icon
Pages 910-912 | Received 24 Apr 2023, Accepted 24 Apr 2023, Published online: 11 May 2023

References

  • LeBlanc TW, Erba HP. Shifting paradigms in the treatment of older adults with AML. Semin Hematol. 2019;56(2):110–117.
  • LeBlanc TW, Fish LJ, Bloom CT, et al. Patient experiences of acute myeloid leukemia: a qualitative study about diagnosis, illness understanding, and treatment decision-making. Psychooncology. 2017;26(12):2063–2068.
  • Nissim R, Zimmermann C, Minden M, et al. Abducted by the illness: a qualitative study of traumatic stress in individuals with acute leukemia. Leuk Res. 2013;37(5):496–502.
  • LeBlanc TW. Shared decision-making in acute myeloid leukemia. Semin Oncol Nurs. 2019;35(6):150958.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728–1740.
  • de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023. DOI:10.1182/bloodadvances.2022009411
  • DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
  • Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–1531.
  • Daver N, Perl AE, Maly J, et al. Venetoclax plus gilteritinib for FLT3-Mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2022;40(35):4048–4059.
  • LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care – hearing the patient voice at greater volume. Nat Rev Clin Oncol. 2017;14(12):763–772.
  • LeBlanc TW, Abernethy AP. Quality of life in higher resolution: the next generation of comparative effectiveness research in malignant hematology. Haematologica. 2013;98(6):823–824.
  • Pratz KW, Panayiotidis P, Recher C, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12(4):71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.